Baidu (BIDU) Offering Possible 10.25% Return Over the Next 23 Calendar Days

Baidu's most recent trend suggests a bearish bias. One trading opportunity on Baidu is a Bear Call Spread using a strike $100.00 short call and a strike $110.00 long call offers a potential 10.25% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $100.00 by expiration. The full premium credit of $0.93 would be kept by the premium seller. The risk of $9.07 would be incurred if the stock rose above the $110.00 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Baidu is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Baidu is bearish.

The RSI indicator is at 29.96 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Baidu

Alphabet's Google Launches Coronavirus Website in the U.S.
Mon, 23 Mar 2020 15:09:03 +0000
Alphabet's (GOOGL) Google launches a coronavirus website in the United States in a bid to educate people about the deadly illness and thereby slow the spread of the virus.

Baidu Collaborates with Aardman to Promote "A Shaun the Sheep Movie: Farmageddon"
Mon, 23 Mar 2020 13:00:00 +0000
Baidu, Inc. (Nasdaq: BIDU) and multi-award-winning animation studio, Aardman, have today announced a new collaboration to bring characters from Aardman’s newest feature film "A Shaun the Sheep Movie: Farmageddon" to Facemoji Keyboard users in the United States and Baidu IME users in China.

Alibaba Pitches Diagnostic Tool to Europe in China Outreach Move
Thu, 19 Mar 2020 10:10:50 +0000
(Bloomberg) — Alibaba Group is offering Europe’s embattled health systems a cloud-based coronavirus diagnostic tool it says it has successfully tried in China’s hospitals.The move by billionaire co-founder Jack Ma’s technology giant comes amid a bigger push by China to promote its efforts to contain the pandemic that started in the city of Wuhan and was left undiagnosed for a few weeks before spreading to the rest of the world. The company said it presented its machine-learning software for chest scans to health-care representatives in France and Italy.Alibaba’s efforts come as China and its top technology companies step up their outreach in Europe, showcasing virus-diagnosis and analysis tools. Telecoms giant Huawei Technologies said it offered Italian hospitals video conferencing and wireless connectivity capabilities. Internet search engine Baidu is proposing an algorithm to analyze the virus’s biological structure.As Europe becomes the epicenter of the virus, Beijing’s diplomatic and material efforts in the fight against the outbreak coincide with what’s seen as an attempt by the Trump administration to distance itself from the region.“Alibaba and other private companies are enrolled by China’s government in its long term plan: show their ability to be an ally for Europe, and pass the message that the U.S. is failing to help them,” said Antoine Bondaz, a researcher at the Strategic Research Foundation in Paris.France wouldn’t refuse the help being offered, and that if Alibaba wanted to contribute to research and diagnosis it could be allowed to, a French government official said, declining to be named in line with internal policy. The health ministry said it hasn’t received a proposal from Alibaba, adding that the “techniques have not been validated.” The diagnostic tool is also seen as costly and time-consuming.Alibaba, which has been expanding its European footprint in the payments and retail sectors, claims its software, developed at its research center called Damo, can diagnose the COVID-19 virus quickly and with 96% accuracy. The company says it has tested the product in China on 5,000 patients.Artificial intelligence-powered scans have been increasingly used in hospitals, and companies like Alphabet Inc.’s Google have developed data-learning solutions to help doctors diagnose diseases like cancer.In Europe, no private company or research lab has come forward with a broad diagnosis solution so far. Atos SE, the big data and cybersecurity company, said it has offered computing capabilities to reproduce and model the 3D atomic structure of the virus to labs in Spain and France.In the U.S., Alphabet Inc.’s health-care unit Verily ran tests for about 20 people on its first day screening the virus on Tuesday in California. Verily is a questionnaire-based diagnostic tool. Potential patients answer questions to determine if they need testing and are then redirected when required to Verily’s two testing sites where another sample is taken, Bloomberg reported.Meanwhile, in Italy, Huawei said it donated hospitals in Milan protective suits and 200,000 masks. Thomas Miao, chief executive officer of Huawei Italy, said the company also offered equipment for wireless networks to about 10 temporary hospitals and said it’s working with partners to create a video-conferencing platform for a real-time connection between hospitals.Alibaba said it shipped two million masks to the continent through Belgium on Friday.On Wednesday, the company published a “digital handbook” to “share their learnings from screening, to diagnosis and treatment of patients who contracted COVID-19, as well as sanitation and facility management.” It also proposed a cloud-based information sharing platform for doctors.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

China's Internet Stocks Can't Hide From This Virus
Thu, 19 Mar 2020 04:11:33 +0000
(Bloomberg Opinion) — As recently as a month ago, investors in China’s internet stocks were clutching on to the belief that these companies would sail through the coronavirus epidemic unscathed.Alibaba Group Holding Ltd., for example, was trading near historic highs despite the e-commerce giant’s chief financial officer admitting days before that its biggest business would decline as a result of the squeeze on consumer spending. By the time Baidu Inc. reported two weeks later, shares of the search-engine provider had lost 11.7%, while those of Alibaba were down 6.4% and social media powerhouse Tencent Holdings Ltd. had slipped 6.2%.Just as investors should have known in mid-February that there was trouble ahead, they’d be well-advised to look at the reality that’s presented to them now and be just as circumspect. China may have gotten past the worst of Covid-19, but the world is just starting to grapple with it and a major economic shock is looming. Now, as we digest Tencent’s fourth-quarter numbers and muddy outlook, these stocks have continued to drop. As have group-buying outfit Pinduoduo Inc. and internet companies Sina Corp. and Weibo Corp.Yet despite declines of a third or more in market value, some of China’s internet darlings are trading at levels seen as recently as three months ago. Tencent, for example, is back where it was Dec. 5. This indicates that investors aren’t pricing in a big economic jolt, but merely a minor bump on the highway of fast growth and climbing profits.In its investor conference call late Wednesday, Tencent didn’t give explicit details on what to expect this quarter. The company did note that the payments business, now one of its fastest-growing units, will post a drop in revenue, offset by a reduction in marketing costs. By comparison, Baidu, Weibo, and Sina all gave specific sales guidance — each predicted declines of 15% to 20% from a year earlier.It’s clearly going to be a tough first quarter, but executives spent much time on their conference calls talking up their future prospects in the belief that this is a minor blip. Robin Li, Baidu’s chairman and chief executive, defended his optimism by claiming that expenditure will merely be delayed: “If you plan to get married, you are still going to marry. If you're trying to buy a car, you are still buying a car.”I can’t help wondering if these business leaders are looking too closely at China’s Covid-19 case count, and correlating a decline in new patients to an immediate rebound in revenue. Certainly, the mood on the ground has brightened and workers are returning to their posts.However, they may not sufficiently be taking on board that the disease has gone global. The disparate attempts in Europe and the Americas to bring it under control mean that any resolution won’t come quickly. It may be the case that with their revenue coming almost exclusively from domestic consumers, they believe a wider meltdown won’t cause much pain.That may be a little naive. Exports account for an important portion of China’s gross domestic product and occupy a significant part of its labor force. Foxconn Technology Group, for example, is the largest private employer in China and gets more than half its revenue from Apple Inc. If orders at these businesses dry up, Chinese consumers will need to reduce expenditure. Last year, I noted that what may save Chinese internet companies is their shift to a post-growth era by trimming costs such as marketing, which some pragmatic executives have done. They’re going to need to adapt again, this time to reflect a world that truly is connected, and where an external shock could quickly become a local problem. Chinese tech companies may think they’ve got through the worst of the storm. They’d better brace themselves for the fact that there is nowhere to hide.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Tim Culpan is a Bloomberg Opinion columnist covering technology. He previously covered technology for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

GOOGL, MSFT & Others to Watch in Fight Against Coronavirus
Wed, 18 Mar 2020 14:47:16 +0000
Strong endeavors of technology companies like Alphabet (GOOGL), Microsoft and others to combat COVID-19 remain noteworthy.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.